by emma
6. October 2011 16:01
Sanofi Pasteur has invested $300 million in plans to open a new vaccine manufacturing plant in India by March 2012.
The new plant aims to help expand the company’s vaccine capabilities, following the acquisition of India’s Shantha Biotech for $784 million in 2009.
However, the deal carried manufacturing defects forced by the WHO to cancel pre-qualification of the vaccine Shan5, costing Sanofi hundreds of millions of dollars.
But Chris Viehbacher, CEO of Sanofi, said to the Business Standard: “We have implemented all the corrective measures. And we are quite positive about the relationship with Shantha and will be participating in global tenders once the pre-qualification process is completed for low-cost and high-quality vaccines.”
By 2015, Sanofi expects 30% of its total sales to come from the US, 33% from Europe and the rest from emerging markets.
ce527e9a-3134-412c-ab23-a645dd7ac870|0|.0
Tags: Sanofi, Sanofi Pasteur, 300 million, India, Indian, vaccine, plant, vaccination, manufacturing, March 2012, company, Shantha Biotech, 784 million, 2009, WHO, Shan5, Chris Viehbacher, CEO, Business Standard, low cost, high quality, treatment, therapy, medication, medicine, drugs, pharma, pharmaceuticals, biotech, Shantha, Emerging Markets, market, sales, medical sales, pharmaceutical sales, Europe, USA, US
News
Subscribe